DTx is a group of flexible, innovative thinkers who are determined to solve one of the biggest challenges limiting the development of genetic medicines. Anchored by their expertise in RNA therapeutics and their proprietary FALCON™ platform, they’ve developed a unique pipeline of novel therapeutic candidates to help patients with ocular, neuromuscular and CNS diseases.